Literature DB >> 6189456

Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome.

T Ruzicka, S Glück.   

Abstract

We determined the histamine content in the skin of 22 adults with atopic dermatitis, one patient with hyper-IgE-syndrome, and 20 controls by the enzymatic double isotope assay. In addition, we performed a pilot study of histamine degradation in the skin. We tested, furthermore, the releasability of histamine from skin sections of patients with atopic dermatitis and healthy controls upon challenge with acetylcholine, anti-IgE, and compound 48/80. Histamine was also determined in 13 plasma specimens and was always less than 1 ng/ml. The mean +/- SEM histamine concentration in the skin was 196 +/- 30 ng/mg protein in controls and 262 +/- 68 ng/mg protein in atopic dermatitis (no statistically significant difference). One control and three patients with atopic dermatitis exhibited a slight, the hyper-IgE patient a marked, elevation of the skin histamine content. No gross differences in the degradation rate of histamine were observed between patients and controls. Acetylcholine and 48/80 induced the same histamine release in both groups; with anti-IgE, almost the double amount of histamine was released from the skin of atopic dermatitis patients as compared to controls. These findings suggest an enhanced releasability of histamine upon immunologic challenge in atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189456     DOI: 10.1007/bf00516553

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  21 in total

1.  Skin histamine levels in chronic atopic dermatitis.

Authors:  H H JOHNSON; G A DEOREO; W P LASCHEID; F MITCHELL
Journal:  J Invest Dermatol       Date:  1960-04       Impact factor: 8.551

2.  Compound 48/80: a potent histamine liberator.

Authors:  W D M PATON
Journal:  Br J Pharmacol Chemother       Date:  1951-09

3.  Enzymatic histamine degradation by human skin.

Authors:  D Francis; M W Greaves; S Yamamoto
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

4.  Localization and content of histamine in normal and diseased skin.

Authors:  L Juhlin
Journal:  Acta Derm Venereol       Date:  1967       Impact factor: 4.437

5.  Histamine receptor--bearing peripheral T lymphocytes in patients with allergies.

Authors:  H Verhaegen; W De Cock; J De Cree
Journal:  J Allergy Clin Immunol       Date:  1977-03       Impact factor: 10.793

Review 6.  Mechanisms of histamine release in anaphylactic and anaphylactoid reactions.

Authors:  W Kazimierczak; B Diamant
Journal:  Prog Allergy       Date:  1978

7.  In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release.

Authors:  L M Lichtenstein; D A Levy; K Ishizaka
Journal:  Immunology       Date:  1970-11       Impact factor: 7.397

8.  Increased sensitivity of lymphocytes from atopic individuals to histamine-induced suppression.

Authors:  I L Strannegård; O Strannegård
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

9.  Complement-induced histamine release from human basophils. III. Effect of pharmacologic agents.

Authors:  W A Hook; R P Siraganian
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

10.  The site of action of the histamine releaser compound 45/80 in causing mast cell degranulation.

Authors:  R H Hino; C K Lau; G W Read
Journal:  J Pharmacol Exp Ther       Date:  1977-03       Impact factor: 4.030

View more
  8 in total

Review 1.  Rational use of antihistamines in allergic dermatological conditions.

Authors:  C Advenier; C Queille-Roussel
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  Skin mast cell releasability in dogs with atopic dermatitis.

Authors:  F DeMora; G García; A Puigdemont; M Arboix; L Ferrer
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

3.  Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.

Authors:  T Yoshioka; I Hikita; M Asakawa; T Hirasawa; M Deguchi; T Matsutani; H Oku; T Horikawa; A Arimura
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages.

Authors:  Susanne Mommert; Lisanne Ratz; Holger Stark; Ralf Gutzmer; Thomas Werfel
Journal:  Inflamm Res       Date:  2018-03-29       Impact factor: 4.575

5.  Histamine up-regulates oncostatin M expression in human M1 macrophages.

Authors:  Susanne Mommert; Marius Hüer; Katrin Schaper-Gerhardt; Ralf Gutzmer; Thomas Werfel
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

6.  Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages.

Authors:  Susanne Mommert; Judith Tabea Schaper; Katrin Schaper-Gerhardt; Ralf Gutzmer; Thomas Werfel
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

7.  Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model.

Authors:  M Gschwandtner; M Mildner; V Mlitz; F Gruber; L Eckhart; T Werfel; R Gutzmer; P M Elias; E Tschachler
Journal:  Allergy       Date:  2012-11-15       Impact factor: 13.146

8.  Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro.

Authors:  Dominika Wcisło-Dziadecka; Beniamin Grabarek; Nikola Zmarzły; Aleksandra Skubis; Bartosz Sikora; Celina Kruszniewska-Rajs; Joanna Gola; Urszula Mazurek; Eugeniusz Kucharz
Journal:  Biomed Res Int       Date:  2018-01-02       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.